No registrations found.
ID
Source
Health condition
autoimmunity GPBP leukocytes
Sponsors and support
Intervention
Outcome measures
Primary outcome
The expression of GPBP on different subsets of leukocytes will be determined with flow cytometric analyses. With these experiments, we are able to describe which specific leukocytes express GPBP. Moreover, since we will analyse both autoimmune and healthy subjects, differences between GPBP expression on particular cell subsets in changing inflammatory conditions might be discovered.
Secondary outcome
The cells that express GPBP (as determined with the flow cytometric analyses of aim 1) will be brought in culture to perform in vitro experiments to determine the exact function of GPBP on these cells. Various assays exist to determine immune cell function in vitro, e.g. cytotoxicity assays for NK cells and T cells, phagocytosis measurements for macrophages, … Dependent on the cell types that express GPBP, suitable assays will be chosen. The experiments will be performed in GPBP depleted and GPBP enhanced conditions. So these experiments will give us insights how GPBP can modulate immune cell activation and function.
Background summary
The Goodpasture antigen binding protein (GPBP) is a protein kinase that binds and phosphorylates collagen. Increased GPBP expression has been found in different autoimmune diseases. However, the cells that produce this GPBP are not known yet. Moreover, the exact function of the protein in the immune response is also not known. Our preliminary results indicate that GPBP is able to interact with proteins of the innate immune system and that it is expressed on leukocytes involved in the innate immune response. The aim of this study is to isolate leukocytes from both patients with an autoimmune disease and healthy controls in order to determine expression levels and functions of GPBP in these cells.
Study objective
The Goodpasture antigen binding protein is able to modify the activation of the immune response, therefore influencing the pathology of autoimmune diseases.
Study design
N/A
Intervention
N/A
Pilar Martinez
Maastricht 6229 ER
The Netherlands
+31 (0)43 3881042
p.martinez@maastrichtuniversity.nl
Pilar Martinez
Maastricht 6229 ER
The Netherlands
+31 (0)43 3881042
p.martinez@maastrichtuniversity.nl
Inclusion criteria
Autoimmune patients:
1. 18 - 50 years old;
2. Diagnosed with myasthenia gravis or multiple sclerosis.
Healthy controls:
1. 18 – 50 years old.
Exclusion criteria
Minors or incapacitated adults will not be included in the study. Subjects that do not want to give their informed consent will not be included.
Healthy controls that have had previous immune-related diseases (e.g chronic inflammatory reactions, autoimmune disease, immunosuppressive treatment, …) will be excluded from this study, since the inflammatory response of these patients can be disturbed.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL2534 |
| NTR-old | NTR2652 |
| CCMO | NL33086.068.10 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON34337 |